Fate Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FATE | IPSC | AUTL | 2126.HK | CHRS | ALLO | |
|---|---|---|---|---|---|---|
| Market cap | 250.42M | 302.40M | 367.30M | 1.11B | 131.36M | 411.13M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.2 | -3.7 | -2.2 | -3.0 | -1.3 | -1.9 |
| Price/book | 1.6 | 1.3 | 4.9 | 2.0 | 2.2 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +100.96% | +209.26% | +1.47% | −31.72% | −42.95% | +13.33% |
| Today | +2.45% | +9.87% | −2.47% | +7.91% | +5.54% | +6.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FATE news ›Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
The Manila Times About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived
Analyzing Fate Therapeutics (FATE) & Its Peers
Posted by Tristan Rich on Nov 3rd, 2026 Fate Therapeutics (NASDAQ:FATE – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Fate Therapeutics to…
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Average Target Price of $5.90 According to Analysts
View Our Latest Report on Fate Therapeutics Fate Therapeutics stock opened at $2.01 on Tuesday. The firm has a market capitalization of $240.84 million, a price-to-earnings ratio of -1.91 and a beta of 2.52. The firm's fifty day moving…
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive ... Fate Therapeutics Announces Receipt…
Wedbush Remains a Buy on Fate Therapeutics (FATE)
Wedbush analyst maintained a Buy rating on Fate Therapeutics today and set a price target of $7.00. In a report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target. Based on Fate…
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT…
Fate Therapeutics, Inc. Announces Appointment of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, Effective October 12, 2026
Fate Therapeutics, Inc. appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026. Mr. Harrell brings more than 25 years of commercial... appointed Jamie Harrell as Senior Vice…
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index
Fate Therapeutics, Inc. dropped from Russell 3000E Index... Biotechnology & Medical Research Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell 3000E Index
Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate
Fate Therapeutics, Inc. had its Investigational New Drug application for FT839 cleared by the U.S. Food and Drug Administration . FT839 is the Company?s next-generation, off-the-shelf CAR T-cell...
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- marketscreener.com7
- markets.financialcontent.com3
- marketbeat.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.